Hansoh Pharmaceutical (03692.HK) Announces NMPA Approval for Clinical Trials of Investigational Drug HS-20108 Injection

Hansoh Pharma (03692) announced that the innovative drug HS-20108 Injection, independently developed by the group, has received clinical trial approval from the China National Medical Products Administration (NMPA). The company plans to conduct clinical trials for advanced solid tumors, such as small cell lung cancer and neuroendocrine tumors.